GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas

GPR64, Screened from Ewing Sarcoma Cells, Is a Potential Target for Antibody-Based Therapy for Various Sarcomas

Ewing sarcoma is an aggressive and the second most common bone tumor in adolescent and young adult patients. The 5-year survival rate is 60–70% for localized disease but 30% for patients with metastases. Here, we aimed to identify a therapeutic target for Ewing sarcoma and evaluate antibody-based th...

Full description

Bibliographic Details
Main Authors: Koichi Nakamura, Kunihiro Asanuma, Takayuki Okamoto, Keisuke Yoshida, Yumi Matsuyama, Kouji Kita, Tomohito Hagi, Tomoki Nakamura, Akihiro Sudo
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
Ewing sarcoma
GPR64
antibody-based therapeutics
epididymis
sarcomas
Online Access:https://www.mdpi.com/2072-6694/14/3/814

Internet

https://www.mdpi.com/2072-6694/14/3/814

Similar Items